Research Alliance Corp IV(RACD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 14.55% | Shs Outstand | 7.8M | Perf Week | -10.26% |
| Market Cap | 0.10B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 7.8M | Perf Month | -12.5% |
| Enterprise Value | 0.10B | PEG | - | EPS next Q | - | Inst Own | 27.2% | Short Float | 0.03% | Perf Quarter | -2.96% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | - | Short Ratio | 0.3 | Perf Half Y | - |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.00M | Perf YTD | 1.45% |
| Book/sh | 0 | P/C | 868.52 | EPS past 3/5Y | - | ROE | - | 52W High | -23.02% ($13.64) | Perf Year | - |
| Cash/sh | 0.01 | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 5% ($10.00) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | - | Gross Margin | - | Volatility(W/M) | 4.88% 5.25% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.6 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.25 | EPS Q/Q | - | Profit Margin | - | RSI (14) | 34.64 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.25 | Sales Q/Q | - | SMA20 | -9.3% ($11.58) | Beta | - | Target Price | - |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -10.21% ($11.69) | Rel Volume | 0.34 | Prev Close | $10.63 |
| Employees | - | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -8.56% ($11.48) | Avg Volume(3M) | 0.01M | Price | $10.5 |
| IPO | 2026/7/13 | Option/Short | No/Yes | Trades | 44 | Volume | 2,661 | Change | -1.22% |
🧬 This is a shell company (SPAC) seeking a merger target in the healthcare sector. It has no operating business of its own and was set up to hold public offering proceeds in a trust account while searching for a merger target in the areas of drug development and commercialization, diagnostics, and healthcare technology and services. The structure is sponsored by an investment group specializing in bio and healthcare.
Over the past 1 year, on the lower side
23% below its 1-year high.
Traded less than usual. That is 34% of its average volume.
Company yardsticks do not fit here, so profitability, valuation and earnings are left out. The other verdicts still apply.
Long-term returns are roughly flat
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 27.2%.
Tap to view numbers
It ranks #1236 of 1433 in the industry
Based on market cap of $96M.
CANG#1235 Cango Inc $97M PER - RACD#1236 Research Alliance Corp IV $96M PER - 
FAQ
What kind of company is RACD?
RACD belongs to the Financial sector and operates in the Shell Companies industry.
What is the market cap of RACD?
The market cap of RACD is approximately $96M, ranking 4,485 within its sector.
What is the 52-week high and low for RACD?
RACD has recorded a 52-week high of $13.64 and a low of $10.00.
